NASDAQ:FATE Fate Therapeutics (FATE) Stock Price, News & Analysis → AI healthcare stock poised for 36,996% growth? (From Behind the Markets) (Ad) Free FATE Stock Alerts $7.34 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$7.23▼$7.6450-Day Range$4.53▼$8.3552-Week Range$1.63▼$8.83Volume2.72 million shsAverage Volume2.95 million shsMarket Capitalization$728.42 millionP/E RatioN/ADividend YieldN/APrice Target$6.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Fate Therapeutics alerts: Email Address Fate Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside8.3% Downside$6.73 Price TargetShort InterestBearish15.17% of Float Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews Sentiment0.78Based on 12 Articles This WeekInsider TradingSelling Shares$199,732 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.89) to ($1.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.57 out of 5 starsMedical Sector310th out of 938 stocksBiological Products, Except Diagnostic Industry44th out of 153 stocks 2.0 Analyst's Opinion Consensus RatingFate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on 2 buy ratings, 8 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.73, Fate Therapeutics has a forecasted downside of 8.3% from its current price of $7.34.Amount of Analyst CoverageFate Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.17% of the float of Fate Therapeutics has been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Fate Therapeutics has recently decreased by 2.45%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldFate Therapeutics does not currently pay a dividend.Dividend GrowthFate Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFate Therapeutics has received a 75.52% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fate Therapeutics is -0.70. Previous Next 3.2 News and Social Media Coverage News SentimentFate Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Fate Therapeutics this week, compared to 3 articles on an average week.Search Interest18 people have searched for FATE on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fate Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $199,732.00 in company stock.Percentage Held by InsidersOnly 5.04% of the stock of Fate Therapeutics is held by insiders.Percentage Held by Institutions97.54% of the stock of Fate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fate Therapeutics are expected to grow in the coming year, from ($1.89) to ($1.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fate Therapeutics is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fate Therapeutics is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFate Therapeutics has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsAI healthcare stock poised for 36,996% growth?Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...Get the name of the stock here... About Fate Therapeutics Stock (NASDAQ:FATE)Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More FATE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FATE Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by BrokeragesMarch 26, 2024 | americanbankingnews.comKiromic BioPharma (NASDAQ:KRBP) versus Fate Therapeutics (NASDAQ:FATE) Critical SurveyMarch 28, 2024 | Behind the Markets (Ad)AI healthcare stock poised for 36,996% growth?Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...March 24, 2024 | benzinga.comFate Therapeutics Stock (NASDAQ:FATE), Quotes and News SummaryMarch 24, 2024 | americanbankingnews.comFate Therapeutics (NASDAQ:FATE) Trading Down 7%March 22, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Fate Therapeutics, Inc. Increased by Analyst (NASDAQ:FATE)March 20, 2024 | americanbankingnews.comHC Wainwright Reiterates "Neutral" Rating for Fate Therapeutics (NASDAQ:FATE)March 19, 2024 | markets.businessinsider.comEvaluating Fate Therapeutics: Insights From 5 Financial AnalystsMarch 28, 2024 | Behind the Markets (Ad)AI healthcare stock poised for 36,996% growth?Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...March 19, 2024 | markets.businessinsider.comFate Therapeutics Prices $100 Mln Of Public Offering, Concurrent Private PlacementMarch 19, 2024 | msn.comFate Therapeutics announces pricing of $100M underwritten offering and concurrent private placementMarch 19, 2024 | globenewswire.comFate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private PlacementMarch 16, 2024 | finance.yahoo.comFATE Apr 2024 5.000 putMarch 16, 2024 | finance.yahoo.comFATE Aug 2024 5.000 putMarch 16, 2024 | finance.yahoo.comFATE Apr 2024 7.500 putMarch 14, 2024 | msn.comVindictus: Defying Fate is worth trying for free even if you never played the MMOMarch 7, 2024 | finance.yahoo.comFATE Mar 2024 10.000 putMarch 6, 2024 | finanznachrichten.deFate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)March 5, 2024 | globenewswire.comFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | finance.yahoo.comFate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | globenewswire.comFate Therapeutics to Present at Upcoming March Investor ConferencesMarch 1, 2024 | markets.businessinsider.comFate Therapeutics: Buy Rating Affirmed Amid Promising Pipeline and Upcoming Oncology CatalystsFebruary 29, 2024 | finance.yahoo.comFate Therapeutics, Inc. (NASDAQ:FATE) Just Reported And Analysts Have Been Lifting Their Price TargetsFebruary 28, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Merus (MRUS)February 28, 2024 | markets.businessinsider.comFate Therapeutics: Hold Rating Maintained Amid Anticipation of Pivotal Clinical DataFebruary 28, 2024 | finance.yahoo.comFate Therapeutics Full Year 2023 Earnings: EPS Beats ExpectationsFebruary 28, 2024 | uk.finance.yahoo.comQ4 2023 Fate Therapeutics Inc Earnings CallSee More Headlines Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today3/28/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FATE CUSIPN/A CIK1434316 Webwww.fatetherapeutics.com Phone(858) 875-1800FaxN/AEmployees181Year FoundedN/APrice Target and Rating Average Stock Price Target$6.80 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside-8.8%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,930,000.00 Net Margins-253.30% Pretax Margin-253.30% Return on Equity-38.17% Return on Assets-28.42% Debt Debt-to-Equity RatioN/A Current Ratio8.48 Quick Ratio8.48 Sales & Book Value Annual Sales$63.53 million Price / Sales11.65 Cash FlowN/A Price / Cash FlowN/A Book Value$3.74 per share Price / Book1.99Miscellaneous Outstanding Shares99,240,000Free Float94,236,000Market Cap$740.33 million OptionableOptionable Beta1.67 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. J. Scott Wolchko (Age 54)Founder, CEO, President & Director Comp: $645kMr. Edward J. Dulac III (Age 48)Chief Financial Officer Comp: $455kMs. Cindy R. Tahl J.D. (Age 51)General Counsel, Corporate Secretary & Compliance Officer Comp: $455kDr. Bahram Valamehr Ph.D. (Age 47)Chief Research & Development Officer Comp: $455kMr. Jim Beitel M.B.A.Senior Vice President of Corporate DevelopmentDr. Jerome Bressi Ph.D.Senior Vice President of Regulatory & QualityDr. Barbara HickingbottomSenior VP of Clinical DevelopmentMore ExecutivesKey CompetitorsGracell BiotechnologiesNASDAQ:GRCLIcosavaxNASDAQ:ICVXVoyager TherapeuticsNASDAQ:VYGRHarpoon TherapeuticsNASDAQ:HARPGlycoMimeticsNASDAQ:GLYCView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 1,614,988 shares on 3/11/2024Ownership: 9.365%Goldman Sachs Group Inc.Bought 96,527 shares on 3/1/2024Ownership: 0.596%Price T Rowe Associates Inc. MDSold 923,505 shares on 2/16/2024Ownership: 0.055%GSA Capital Partners LLPSold 210,426 shares on 2/16/2024Ownership: 0.044%Citadel Advisors LLCBought 2,000 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions FATE Stock Analysis - Frequently Asked Questions Should I buy or sell Fate Therapeutics stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares. View FATE analyst ratings or view top-rated stocks. What is Fate Therapeutics' stock price target for 2024? 11 equities research analysts have issued twelve-month price targets for Fate Therapeutics' stock. Their FATE share price targets range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $6.73 in the next year. This suggests that the stock has a possible downside of 8.3%. View analysts price targets for FATE or view top-rated stocks among Wall Street analysts. How have FATE shares performed in 2024? Fate Therapeutics' stock was trading at $3.74 on January 1st, 2024. Since then, FATE stock has increased by 96.3% and is now trading at $7.34. View the best growth stocks for 2024 here. When is Fate Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our FATE earnings forecast. How were Fate Therapeutics' earnings last quarter? Fate Therapeutics, Inc. (NASDAQ:FATE) announced its earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.12. The biopharmaceutical company had revenue of $1.68 million for the quarter, compared to analysts' expectations of $0.85 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 38.17% and a negative net margin of 253.30%. During the same quarter in the previous year, the company earned ($0.58) EPS. What ETF holds Fate Therapeutics' stock? iShares Genomics Immunology and Healthcare ETF holds 348,530 shares of FATE stock, representing 0.86% of its portfolio. What is Scott Wolchko's approval rating as Fate Therapeutics' CEO? 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD). Who are Fate Therapeutics' major shareholders? Fate Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.43%), Vanguard Group Inc. (9.36%), Point72 Asset Management L.P. (3.54%), Monaco Asset Management SAM (2.21%), Federated Hermes Inc. (1.88%) and Vestal Point Capital LP (1.31%). Insiders that own company stock include Bahram Valamehr, Brian T Powl, Cindy Tahl, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal, Yuan Xu and Yu-Waye Chu. View institutional ownership trends. How do I buy shares of Fate Therapeutics? Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FATE) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingInvestors Alert: The Next Big Thing in Weight LossBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.